|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|
| Operating expenses: | |||
| Research and development | |||
| General and administrative | |||
| Total operating expenses | |||
| Loss from operations | |||
| Other income, net: | |||
| Change in fair value of anti-dilution right liability | |||
| Change in fair value of preferred stock tranche liability | |||
| Interest income | |||
| Other (income) expense | |||
| Total other income, net | |||
| Net loss | |||
| Net loss per share of common stock, basic | |||
| Net loss per share of common stock, diluted | |||
| Weighted-average number of common stock outstanding, basic | |||
| Weighted-average number of common stock outstanding, diluted |
Loading...
